{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:13:17Z","timestamp":1696338797967},"reference-count":31,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":777,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Virol."],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1002\/jmv.23673","type":"journal-article","created":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T21:50:41Z","timestamp":1374011441000},"page":"1746-1753","source":"Crossref","is-referenced-by-count":11,"title":["A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C"],"prefix":"10.1002","volume":"85","author":[{"given":"Tasuku","family":"Hara","sequence":"first","affiliation":[{"name":"Department of Hepatology; Toranomon Hospital; Tokyo; Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Akuta","sequence":"additional","affiliation":[{"name":"Department of Hepatology; Toranomon Hospital; Tokyo; Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hepatology; Toranomon Hospital; Tokyo; Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Sezaki","sequence":"additional","affiliation":[{"name":"Department of Hepatology; Toranomon Hospital; Tokyo; Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hepatology; Toranomon Hospital; Tokyo; Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Hosaka","sequence":"additional","affiliation":[{"name":"Department of Hepatology; Toranomon Hospital; Tokyo; Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hepatology; Toranomon Hospital; Tokyo; Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Liver Research Laboratory; Toranomon Hospital; Tokyo; Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Saitoh","sequence":"additional","affiliation":[{"name":"Department of Hepatology; Toranomon Hospital; Tokyo; Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[{"name":"Department of Hepatology; Toranomon Hospital; Tokyo; Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,7,16]]},"reference":[{"key":"10.1002\/jmv.23673-BIB0001|jmv23673-cit-0001","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000086064","article-title":"Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy","volume":"48","author":"Akuta","year":"2005","journal-title":"Intervirology"},{"key":"10.1002\/jmv.23673-BIB0002|jmv23673-cit-0002","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep.23690","article-title":"Amino acid substitution in HCV core region and genetic variation near IL28B gene predict viral response to telaprevir with peginterferon and ribavirin","volume":"52","author":"Akuta","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/jmv.23673-BIB0003|jmv23673-cit-0003","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1159\/000323526","article-title":"Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment","volume":"55","author":"Akuta","year":"2012","journal-title":"Intervirology"},{"key":"10.1002\/jmv.23673-BIB0004|jmv23673-cit-0004","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.23691","article-title":"Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection","volume":"52","author":"Asahina","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/jmv.23673-BIB0005|jmv23673-cit-0005","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1111\/j.1478-3231.2010.02411.x","article-title":"New direct-acting antivirals' combination for the treatment of chronic hepatitis C","volume":"31","author":"Asselah","year":"2011","journal-title":"Liver Int"},{"key":"10.1002\/jmv.23673-BIB0006|jmv23673-cit-0006","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/infdis\/jir210","article-title":"IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C","volume":"204","author":"Chayama","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1002\/jmv.23673-BIB0007|jmv23673-cit-0007","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199601113340203","article-title":"Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection","volume":"334","author":"Enomoto","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1002\/jmv.23673-BIB0008|jmv23673-cit-0008","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1002\/jmv.23673-BIB0009|jmv23673-cit-0009","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"H\u00e9zode","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1002\/jmv.23673-BIB0010|jmv23673-cit-0010","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1478-3231.2009.02064.x","article-title":"Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C","volume":"30","author":"Honda","year":"2010","journal-title":"Liver Int"},{"key":"10.1002\/jmv.23673-BIB0011|jmv23673-cit-0011","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep.510290439","article-title":"Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C; a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis","volume":"29","author":"Ikeda","year":"1999","journal-title":"Hepatology"},{"key":"10.1002\/jmv.23673-BIB0012|jmv23673-cit-0012","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.amjmed.2008.09.045","article-title":"Necessities of interferon therapy in elderly patients with chronic hepatitis C","volume":"122","author":"Ikeda","year":"2009","journal-title":"Am J Med"},{"key":"10.1002\/jmv.23673-BIB0013|jmv23673-cit-0013","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-129-2-199807150-00005","article-title":"Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C, Osaka Hepatocellular Carcinoma Prevention Study Group","volume":"129","author":"Imai","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1002\/jmv.23673-BIB0014|jmv23673-cit-0014","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.20984","article-title":"Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C","volume":"43","author":"Iwasaki","year":"2006","journal-title":"Hepatology"},{"key":"10.1002\/jmv.23673-BIB0015|jmv23673-cit-0015","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1073\/pnas.87.24.9524","article-title":"Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis","volume":"87","author":"Kato","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/jmv.23673-BIB0016|jmv23673-cit-0016","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199904223401602","article-title":"Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group","volume":"340","author":"Kenny-Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1002\/jmv.23673-BIB0017|jmv23673-cit-0017","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2011.07.016","article-title":"Telaprevir with peginterferon and ribavirin for treatment-na\u00efve patients chronically infected with HCV of genotype 1 in Japan","volume":"56","author":"Kumada","year":"2011","journal-title":"J Hepatol"},{"key":"10.1002\/jmv.23673-BIB0018|jmv23673-cit-0018","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-127-10-199711150-00003","article-title":"Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy","volume":"127","author":"Marcellin","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1002\/jmv.23673-BIB0019|jmv23673-cit-0019","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/hep.23444","article-title":"Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin","volume":"51","author":"Martinot-Peignoux","year":"2010","journal-title":"Hepatology."},{"key":"10.1002\/jmv.23673-BIB0020|jmv23673-cit-0020","first-page":"202","volume-title":"Hepatology a clinical text book","author":"Mauss","year":"2012"},{"key":"10.1002\/jmv.23673-BIB0021|jmv23673-cit-0021","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1002\/jmv.23673-BIB0022|jmv23673-cit-0022","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1002\/jmv.23673-BIB0023|jmv23673-cit-0023","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/hep.510280632","article-title":"Prognosis of chronic hepatitis C: Results of a large, prospective cohort study","volume":"28","author":"Niederau","year":"1998","journal-title":"Hepatology"},{"key":"10.1002\/jmv.23673-BIB0024|jmv23673-cit-0024","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s100380170047","article-title":"A high-throughput SNP typing system for genome-wide association studies","volume":"46","author":"Ohnishi","year":"2001","journal-title":"J Hum Genet"},{"key":"10.1002\/jmv.23673-BIB0025|jmv23673-cit-0025","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","article-title":"Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy","volume":"132","author":"Shiratori","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1002\/jmv.23673-BIB0026|jmv23673-cit-0026","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"10.1002\/jmv.23673-BIB0027|jmv23673-cit-0027","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/ng1206","article-title":"Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginiedeminase 4, are associated with rheumatoid arthritis","volume":"34","author":"Suzuki","year":"2003","journal-title":"Nat Genet"},{"key":"10.1002\/jmv.23673-BIB0028|jmv23673-cit-0028","article-title":"An exploratory study on telaprevir given every 8\u2009hours at 500 or 750\u2009mg with peginterferon alfa-2b and ribavirin in hepatitis C patients","author":"Suzuki","year":"2012","journal-title":"Hepatol Res"},{"key":"10.1002\/jmv.23673-BIB0029|jmv23673-cit-0029","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"10.1002\/jmv.23673-BIB0030|jmv23673-cit-0030","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","article-title":"Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy","volume":"131","author":"Yoshida","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1002\/jmv.23673-BIB0031|jmv23673-cit-0031","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000087257","article-title":"National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population","volume":"49","author":"Yoshizawa","year":"2006","journal-title":"Intervirology"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.23673","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/jmv.23673\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T16:08:25Z","timestamp":1625328505000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.23673"}},"subtitle":["Telaprevir for Elderly Patients"],"short-title":[],"issued":{"date-parts":[[2013,7,16]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"URL":"https:\/\/doi.org\/10.1002\/jmv.23673","relation":{},"ISSN":["0146-6615"],"issn-type":[{"value":"0146-6615","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7,16]]}}}